UCLA IRB # 06-04-016 "PHASE II TRIAL OF BEVACIZUMAB IN COMBINATION WITH TEMOZ

加州大学洛杉矶分校IRB

• 批准号: 8167096
• 负责人: TIMOTHY CLOUGHESY
• 金额: $ 14.11万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167096
• 关键词: Computer Retrieval of Information on Scientific Projects Database; DNA; Evaluation; Freezing; Funding; Glioblastoma; Grant; Institution; Newly Diagnosed; Patients; Phase II Clinical Trials; Proteins; Radiation; Research; Research Ethics Committees; Research Personnel; Resources; Safety; Sampling; Source; United States National Institutes of Health; bevacizumab; temozolomide; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: Primary Aim To investigate the safety and tolerability in newly-diagnosed patients with glioblastoma of the combination of bevacizumab with temozolomide/radiation To estimate the overall survival in subjects with newly-diagnosed glioblastoma treated with bevacizumab/temozolomide/radiation followed by bevacizumab/temozolomide for 2 years or until progression is detected. Secondary Aims To investigate further the safety and tolerability of bevacizumab/temozolomide/radiation followed by bevacizumab/temozolomide. To isolate DNA, RNA, and protein isolated from frozen and paraffinized archival tumor samples for evaluations.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 具体目的： 主要目的 研究贝伐单抗与替莫唑胺/辐射的新诊断患者的安全性和耐受性 为了估计用贝伐单抗/替莫唑胺/辐射治疗的新诊断的胶质母细胞瘤的受试者的总生存率，然后是贝伐单抗/替莫唑胺2年或直到检测到进展。 次要目标 为了进一步研究贝伐单抗/替莫唑胺/辐射的安全性和耐受性，然后是贝伐单抗/替莫唑胺。 分离从冷冻和石化档案肿瘤样品中分离的DNA，RNA和蛋白质进行评估。